These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17440052)

  • 1. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
    Zhao X; Lapalombella R; Joshi T; Cheney C; Gowda A; Hayden-Ledbetter MS; Baum PR; Lin TS; Jarjoura D; Lehman A; Kussewitt D; Lee RJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2007 Oct; 110(7):2569-77. PubMed ID: 17440052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
    Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
    MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
    Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
    Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
    Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
    Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
    Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
    Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
    Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DuoHexaBody-CD37
    Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
    Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM; Shields J; Garron C; Hu Y; Boutin P; Shankara S; Weber W; Roberts B; Kaplan JM
    Leuk Lymphoma; 2010 Jul; 51(7):1293-304. PubMed ID: 20377308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
    Heider KH; Kiefer K; Zenz T; Volden M; Stilgenbauer S; Ostermann E; Baum A; Lamche H; Küpcü Z; Jacobi A; Müller S; Hirt U; Adolf GR; Borges E
    Blood; 2011 Oct; 118(15):4159-68. PubMed ID: 21795744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
    Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
    Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
    Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
    Robak T
    Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
    Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
    Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemia-associated changes identified by quantitative flow cytometry. III. B-cell gating in CD37/kappa/lambda clonality test.
    Peters RE; Janossy G; Ivory K; al-Ismail S; Mercolino T
    Leukemia; 1994 Nov; 8(11):1864-70. PubMed ID: 7967732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
    Robak T; Robak P; Smolewski P
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1383-90. PubMed ID: 19943209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.